Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · May 29, 2023

Effect of Canagliflozin on the Risk of Non-Genital Skin and Soft Tissue Infections in People With Type 2 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials
Diabetes Obes Metab 2023 May 10;[EPub Ahead of Print], A Kang, B Smyth, BL Neuen, HJL Heerspink, GL Di Tanna, H Zhang, C Arnott, C Hockham, R Agarwal, G Bakris, DM Charytan, D de Zeeuw, T Greene, A Levin, C Pollock, DC Wheeler, KW Mahaffey, V Perkovic, MJ Jardine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading